Safety will be assessed by prevalence of malaria parasitaemia and CRP and inflammation (CRP>5 mg/L) at the end of the intervention and a further 6 months post-intervention; episodes of caregiver reported symptoms (eg, fever, diarrhoea, vomiting, cough) determined by the biweekly and monthly morbidity questionnaire; episodes of unplanned clinical visits and hospitalisations and deaths. The gene discussed is CRP; the disease is malaria.